Status:
TERMINATED
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
Lead Sponsor:
Emory University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Schizophrenia
Eligibility:
MALE
20-50 years
Phase:
NA
Brief Summary
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether...
Detailed Description
TITLE: Aripiprazole effects on reward processing in deficit syndrome schizophrenia Principal Investigator: Erica Duncan, M.D. Background- This is a study of the way people with schizophrenia may feel...
Eligibility Criteria
Inclusion
- Subjects with Schizophrenia:
- Diagnosed with schizophrenia
- Male
- Age 20-50
- Right handed
Exclusion
- No current or past drug or alcohol problems (dependance or abuse)
- Not color blind
- Control Subjects:
- Inclusion Criteria:
- Male
- Age 20-50
- Right handed
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00209027
Start Date
April 1 2005
End Date
April 1 2011
Last Update
December 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033